Last reviewed · How we verify

NCT00415766

Recombinant hCG (Ovitrelle) Vesrus Urinary hCG (Pregnyl) for Triggering Final Oocyte Maturation in High Responders

Status unknown Phase 4 Last updated 18 January 2016
What this trial tests

Phase 4 trial testing rHCG 250ug in Infertility in 150 participants. Status unknown.

Timeline
1 June 2013
Primary endpoint
1 December 2015
1 July 2016

Quick facts

Lead sponsorEugonia
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment150
Start date1 June 2013
Primary completion1 December 2015
Estimated completion1 July 2016
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Eugonia — full company profile →

Who can join

Adults 18 to 39, female only, with Infertility. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

Other Eugonia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00415766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing